Sign In
Buy BSEM
$4.14
-0.0290 (-0.696%)
At Close: Jun 03, 2026
Advanced wound care MedTech company recently reported a record second-quarter with $116.4M in revenue for H1, 2024 POMPANO BEACH, Fla., Aug. 29, 2024 — BioStem Technologies Inc. (OTC: BSEM), a leadi
POMPANO BEACH, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-der
Study supports BioStem's strategic growth initiatives and accelerates product adoption by providing data to healthcare professionals and payers on the benefits of Vendaje POMPANO BEACH, FL, August 21,
POMPANO BEACH, Fla., Aug. 21, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-deri
BioStem Technologies: A New Growth Star In Health Care
05:15am, Wednesday, 21'st Aug 2024
BioStem Technologies has enjoyed exceptional growth in its first year as a public company, with revenues soaring and earnings turning positive. The company's flagship product, AmnioWrap2, has been a m
BioStem Technologies, Inc. (BSEM) Q2 2024 Earnings Call Transcript
11:12pm, Monday, 12'th Aug 2024
BioStem Technologies, Inc. (OTCPK:BSEM) Q2 2024 Results Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executiv
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
04:16pm, Monday, 12'th Aug 2024
POMPANO BEACH, FL, 2024 — BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, reports fina
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
04:14pm, Monday, 12'th Aug 2024
Company reports transformative second-quarter revenue, contributing to a record total of $116.4 million in revenue for the first half of 2024 AmnioWrap2 continues to be a major growth driver achieving
BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
08:00am, Monday, 05'th Aug 2024
Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., August 5, 2024, — BioStem Technologies, Inc.
BioStem Technologies Inc. In A Race To The Top With Innovative Wound-Care Treatments
08:12am, Tuesday, 16'th Jul 2024
Miami, Florida--(Newsfile Corp. - July 16, 2024) - Innovation is the lifeblood of the MedTech sector. Literally.
BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
07:16am, Wednesday, 10'th Jul 2024
POMPANO BEACH, FL, July 10, 2024 – BioStem Technologies Inc.
BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
07:15am, Wednesday, 10'th Jul 2024
POMPANO BEACH, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
08:30am, Wednesday, 26'th Jun 2024
Study published in peer-reviewed journal finds BioStem's products offer overall better treatment efficiency, and greater efficiency in general wound closure POMPANO BEACH, Fla., June 26, 2024 — BioS
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
08:30am, Wednesday, 26'th Jun 2024
POMPANO BEACH, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of
UPDATE -- PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
02:07pm, Monday, 17'th Jun 2024
Please note: this Update is being issued for ticker indexing purposes. The content of the release itself remains the same.
